Government to unveil Bharat Forecasting System on May 26
Developed by Pune-based Indian Institute of Tropical Meteorology (IITM), Bharat Forecasting System (BFS) will provide forecasts with a 6 km resolution — the highest in the world — that would allow forecasters to predict small-scale weather features more accurately.
'We will now be able to issue more localised and accurate weather forecasts,' M. Ravichandran, Secretary, Ministry of Earth Sciences, told PTI.
The new forecasting model, developed by researchers, including Parthasarathy Mukhopadhayay, was made possible due to installation of the new supercomputer Arka at the IITM campus last year with a capacity of 11.77 petaflops (a unit to measure computer processing speed)and storage capacity of 33 petabytes (a petabyte is 1,000 terabytes (TB)).
'The previous supercomputer 'Pratyush' used to take up to 10 hours to run the forecasting model. Arka performs the same data-crunching within four hours,' Mr. Mukhopadhyay told PTI.
Mr. Ravichandran said BFS provides insight into weather events likely to take place in a grid of 6 km by 6 km against the earlier models that gave predictions for a 12 km grid.
He said data from a network of 40 Doppler Weather Radars from across the country will be used to run the BFS model that would enable the weather office to issue more localised forecasts as well as nowcasts — weather forecasts for the next two hours.
Gradually, the number of Doppler radars will increase to 100, which would allow the weather office to issue nowcasts across the country.
BFS can provide 6 km resolution forecasts for the tropical region that falls between 30 degrees South and 30 degrees North latitudes. The Indian mainland extends between 8.4 degrees North and 37.6 degrees North latitudes.
According to Mr. Ravichandran, the global forecast models run by the European, British and U.S. weather offices have a resolution between 9 km and 14 km.
Union Earth Sciences Minister Jitendra Singh is scheduled to dedicate BFS to the nation at a special function here on Monday (May 26, 2025).
'This significant milestone represents a major leap in India's self-reliance in meteorological sciences, enabling more accurate and granular weather forecasts up to panchayat level for disaster risk reduction, agriculture, water resource management and public safety,' a senior official from the Earth Sciences Ministry said.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Hindustan Times
4 hours ago
- Hindustan Times
From no alcohol to vegetarian food, inside Shubhanshu Shukla's ISS farewell
Close your eyes and picture a farewell party. We're sure you're thinking of music, food and a few teary-eyed hugs. But when the goodbye happens hundreds of kilometers above Earth, the situation looks a little different. Aboard the International Space Station, Indian astronaut Shubhanshu Shukla recently received a send-off that was minimal. No clinking glasses, no lavish spread – just floating food pouches, warm camaraderie and a sense of shared achievement, reports News18. Also, in keeping with ISRO tradition, there was no non-vegetarian fare. Shubhanshu Shukla, 39, is a Group Captain and test pilot in the Indian Air Force (HT_PRINT) Also read: Astronaut Shubhanshu Shukla's family: He showed us sunrise from ISS; waiting for him to return tomorrow What's allowed at an ISS farewell? Shukla and a few fellow astronauts were given a low-key but meaningful farewell aboard the ISS, streamed live to Earth, sparking plenty of curiosity online. Is there cake? Can they play music? and much more. While images of astronauts doing rounds online in T-shirts might suggest a relaxed vibe, space life is definitely not casual. In fact, any crew gathering, including farewells, must be coordinated with Earth-based mission control centers in Houston and Moscow. Reportedly, every ceremony and every moment follows strict protocol. Farewells, too, are defined by the 1998 Intergovernmental Agreement and the Crew Code of Conduct (CCOC), signed by space agencies like NASA, Roscosmos, ESA, JAXA and CSA. Even in microgravity, rules guide everything, from who speaks when to what foods are permitted, and no confetti. Also read: India's Shubhanshu Shukla, Axiom-4 crew begin journey back to Earth: When, where they'll land Food items that are allowed Forget the champagne toasts or juicy steaks – those don't fly in space. On the ISS, NASA strictly prohibits alcohol, non-veg meals, or anything intoxicating. Food is limited to vacuum-sealed, pre-approved packets like rehydrated mac and cheese or the occasional chocolate bar. Even utensils need prior clearance. Why so strict? In a closed-loop system where air is recycled, even a strong food smell can throw things off. In space, even celebrations have to follow rules. Muted music, emotional goodbyes Music is allowed aboard the ISS, but only if it doesn't disturb communication or scientific work. Instead, astronauts connect with family through scheduled video calls. FAQs: 1. Who is Shubhanshu Shukla? He (39) is a Group Captain and test pilot in the Indian Air Force and a Gaganyatri with ISRO. 2. What is his current mission? As of July 2025, he's serving as the mission pilot for Axiom Mission 4 to the International Space Station. 3. What kind of food do astronauts eat in space? Pre-approved, astronauts eat pre-packed, dehydrated meals. Also, non-vegetarian food is restricted.
Mint
6 hours ago
- Mint
Sacrifices, trade-offs behind big win, says Glenmark's Saldanha
The road to drug discovery is long, arduous and littered with failure, but the payoff at the end makes it worth the trouble. It's a lesson that India's best pharmaceutical entrepreneurs knew all along. Yet, it took a Glenn Saldanha to prove it. 'We were always resilient in how we approached innovation. I think that's what finally rewarded us," Saldanha, chief executive officer and managing director of Glenmark Pharmaceuticals Ltd, told Mint in an exclusive interview. He was referring to one of the largest deals for an Indian biopharma firm after Glenmark's US-based unit Ichnos Glenmark Innovation (IGI) secured a $700-million exclusive licensing agreement with AbbVie for its blood cancer drug candidate last week. AbbVie will also pay as much as $1.23 billion as various milestones are completed, as well as tiered, double-digit royalties on net sales. ISB 2001, the investigational drug to treat multiple myeloma, is in phase-1 clinical trials and has shown promising data. In a trial with 35 patients who had exhausted all existing lines of therapy unsuccessfully, 79% showed a clinical response to it, and 30% were cancer-free. 'I hope this acts as a catalyst to expanding the innovation landscape in India…we've demonstrated that you can do it," said Saldanha. Last bet ISB 2001, developed on IGI's proprietary BEAT platform, was the firm's last bet. 'There was no plan B," said Saldanha. 'This was pretty much the end of the road. At this point, the technology had to demonstrate that it worked…or we don't know what we would have done as the next thing." The drug had been in discovery over the last five years, while the company had been working on the BEAT platform for about a decade. There were three other assets that the company stopped developing. ISB 2001 has received both the US FDA Orphan Drug and Fast Track designations, highlighting its Orphan Drug designation is given to drugs treating rare diseases, while a fast track designation intends to expedite the development and review of drugs for treating serious conditions and fill unmet medical needs. Following the licensing agreement, AbbVie will take over further development for phase-2 and phase-3 trials before it can file for regulatory approval. The process would typically take four to five years. The market size for multiple myeloma is estimated to grow to $50 billion by 2030. Should the drug hit the markets in 2030, taking into account the tiered double-digit royalties, Glenmark stands to earn an additional $2.02 billion in royalties until 2041, according to research by brokerage Nuvama. The deal validates several aspects of Glenmark, including the strength of IGI's BEAT platform, the potential for ISB 2001 to treat relapsed/refractory multiple myeloma, and its commercial viability following successful clinical trials, said an 11 July note by Motilal Oswal analysts. 'Moreover, AbbVie has established itself as a diversified biopharma leader, combining scientific innovation with strong commercial execution. In oncology, the company has built a robust presence anchored by two cornerstone therapies: Imbruvica, a BTK inhibitor, and Venclexta, a BCL-2 inhibitor. These medicines have transformed the treatment landscape for chronic lymphocytic leukemia and other B-cell malignancies, generating multi-billion-dollar revenues and reinforcing AbbVie's reputation as a pioneer in hematologic cancer," the note added. Huge sacrifices, trade-offs Saldanha has bet on innovation since he took the reins of the company in the late 90s. A few years after Glenmark was listed in 2000, it established its first R&D centre for novel biologics research in Switzerland. Over the years, the company did a number of licensing deals with novel assets. In 2019, it spun off its R&D entity under a new company, Ichnos Sciences, which built on its proprietary BEAT bispecific platform. The two announced the creation of Ichnos Glenmark Innovation (IGI) in 2024. The company's focus on innovation created a lot of frustration for investors and stakeholders, Saldanha said. '[We were] bordering on being called eccentric," he said. The company also had to sell its stake in its active pharmaceutical ingredient (API) division, Glenmark Life Sciences, to pare its debt in 2023, which was approximately ₹4,500-4,600 crore. Glenmark sold 75% stake in the unit to industrial conglomerate Nirma for ₹5,650 crore. The company has made 'huge sacrifices, huge trade-offs," said Saldanha. With the GLS sale, the company had a choice to decide 'which end of the value chain we play", said Saldanha. 'Whether we play on this API stable end of the value chain, and generate revenues like that, or we play on the high end of the value chain, which is innovation." But innovation is not a cost game, he said. 'It's all about being able to understand where the therapy is going and how to come up with solutions." What's next for Glenmark? IGI spends about $70 million annually on new drug research. With the upfront payment it receives, it will be self-funded for the next three to four years, said Saldanha. The company will also look at rewarding shareholders with dividends. Apart from that, there are no immediate investment plans, said Saldanha. 'At least for the next year or two, we won't do anything. We'll just continue regrouping and trying to figure out strategically where we can further add value," he said. The deal is a big event for the company, which 'basically resets the whole agenda for the company", he said. 'We have to really reset and rethink how we want to see the company over the next five to ten years." ISB 2001's early success has validated the BEAT platform. 'We think we've now got it right with the technology…the idea is how can we exploit that technology much more effectively to add more products and do more," said Saldanha. The unit has another asset called ISB 2301, which is in late pre-clinical development and will go to the clinic next year. This drug will target solid tumours, said Saldanha. IGI also has a couple of other early-stage programs. '...over the next three, four years, we will exploit the technology as effectively as possible."
United News of India
6 hours ago
- United News of India
Over 60 space experiments completed on Axiom-4
Bengaluru, July 14 (UNI) The Axiom-4 mission has successfully conducted over 60 scientific experiments aboard the International Space Station (ISS), producing critical data expected to shape future space missions and improve human health in both space and terrestrial environments. These experiments included research into muscle formation (myogenesis), bone health, microalgae sustainability, stem cell behavior, and the growth of edible sprouts in microgravity. The findings are anticipated to play a vital role in developing long-duration spaceflight strategies and enhancing biomedical understanding on Earth. Originally scheduled to return on July 10 after a planned 14-day mission, astronauts Shubhanshu Shukla, Peggy Whitson, Alper Gezeravcı (Kapu), and Slawosz Uznanski had their stay extended due to unfavorable conditions at the splashdown site, according to the European Space Agency (ESA). Another key reason for the delay was the need to complete several ongoing experiments, which required more time for meaningful results. Their return has now been tentatively rescheduled for July 14. Commissioned by Axiom Space, a Houston-based private space company, the mission was carried out in partnership with NASA, ISRO (Indian Space Research Organisation), and ESA (European Space Agency). The Axiom-4 mission had two primary objectives: to enable commercial activities in space and to foster deeper international cooperation in space exploration. The successful collaboration between major space agencies and the private sector is seen as a significant step forward in the evolving landscape of space missions, where science, commerce, and diplomacy converge in low Earth orbit. UNI BDN SSP
